...
首页> 外文期刊>Journal of Hospital Medicine >Prevalence of multidrug-resistant pseudomonas aeruginosa and carbapenem-resistant enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009
【24h】

Prevalence of multidrug-resistant pseudomonas aeruginosa and carbapenem-resistant enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009

机译:2000年至2009年美国住院肺炎和血液感染患者标本中多药耐药的铜绿假单胞菌和耐碳青霉烯的肠杆菌科的患病率

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Antimicrobial resistance complicates antibiotic selection. Pseudomonas aeruginosa (PA), common in pneumonia and blood stream infections (BSIs), is frequently resistant to multiple antimicrobial classes. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a pathogen of concern over the past decade. OBJECTIVE: To determine the prevalence of CRE and multidrug-resistant PA (MDR-PA) in pneumonia and BSI hospitalizations. DESIGN: Survey of data from a nationally representative sample of microbiology laboratories in 217 hospitals in the United States. METHODS/SETTING: We examined Eurofins' The Surveillance Network database from 2000 to 2009 to explore the proportion of all PA in pneumonia and BSI that is MDR. We performed the same analysis for CRE as a proportion of Enterobacteriaceae. We defined MDR-PA as any isolate resistant to ≥3 drug classes. Enterobacteriaceae were CRE if resistant to both a third generation cephalosporin and a carbapenem. RESULTS: We identified 205,526 PA (187,343 pneumonia; 18,183 BSI) and 95,566 Enterobacteriaceae specimens (58,810 pneumonia; 36,756 BSI). The prevalence of MDR-PA was ~15-fold higher than CRE in both infection types (pneumonia: 22.0% MDR-PA vs 1.6% CRE; BSI: 14.7% MDR-PA vs 1.1% CRE). There was a net rise in MDR-PA as a proportion of all PA from 2000 to 2009 (BSI: 10.7%-13.5%; pneumonia: 19.2%-21.7%). The CRE phenotype emerged in 2002 in both infection types, peaking in 2008 at 3.6% in BSI and 5.3% in pneumonia, and stabilized thereafter. CONCLUSIONS: Although CRE organisms have emerged as an important pathogen in BSI and pneumonia, MDR-PA remains more prevalent in the United States.
机译:背景:抗菌素耐药性使抗生素的选择复杂化。铜绿假单胞菌(PA),常见于肺炎和血流感染(BSI),通常对多种抗菌药具有耐药性。在过去十年中,对碳青霉烯类耐药的肠杆菌科(CRE)已成为令人关注的病原体。目的:确定在肺炎和BSI住院治疗中CRE和多药耐药PA(MDR-PA)的患病率。设计:调查来自美国217家医院的全国代表性微生物实验室样本的数据。方法/背景:我们检查了2000年至2009年间Eurofins的监测网络数据库,以探讨肺炎和BSI(即MDR)中所有PA的比例。我们对CRE与肠杆菌科的比例进行了相同的分析。我们将MDR-PA定义为对≥3种药物有抗药性的任何分离株。如果对第三代头孢菌素和碳青霉烯均耐药,则肠杆菌科细菌为CRE。结果:我们确定了205,526 PA(187,343肺炎; 18,183 BSI)和95,566肠杆菌科标本(58,810肺炎; 36,756 BSI)。在两种感染类型中,MDR-PA的患病率均比CRE高约15倍(肺炎:22.0%MDR-PA对1.6%CRE; BSI:14.7%MDR-PA对1.1%CRE)。从2000年到2009年,MDR-PA占所有PA的比例出现了净增长(BSI:10.7%-13.5%;肺炎:19.2%-21.7%)。这两种感染类型的CRE表型均在2002年出现,在2008年达到峰值,BSI为3.6%,肺炎为5.3%,此后趋于稳定。结论:尽管CRE生物已成为BSI和肺炎的重要病原体,但MDR-PA在美国仍然更为普遍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号